33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characterizing the immune effects of enfortumab vedotin (EV) on peripheral blood mononuclear cells (PBMCs) in metastatic urothelial cancer patients (mUC)
    Meeting Abstract

    Gupta, A.; Sevilla, C.; Pihlstrom, N. L.; Liang, S.; Regazzi, A. M.; McCoy, A. S.; Maher, C. A.; Wong, P.; Ahmed, F.; Funt, S. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Association between clonal hematopoiesis and survival after nephrectomy in patients with renal cell carcinoma
    Meeting Abstract

    Khandwala, Y.; Ruthen, N.; Kotecha, R. R.; Russo, P.; Coleman, J.; Reznik, E.; Hakimi, A. A.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Analysis of distinct genomic, transcriptomic, and immune landscapes driven by alterations in androgen production, uptake, and conversion (APUC) genes in metastatic prostate cancers
    Meeting Abstract

    Lacuna, K. P.; Ishani, K.; Boytim, E.; Abida, W.; Morris, M. J.; Antonarakis, E. S.; Hwang, J.; Ryan, C. J.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Digital physiological monitoring for personalized prediction of physical function and fatigue in men with castration sensitive prostate cancer
    Meeting Abstract

    Wax, I.; Markus, A.; Carlson, A.; Scott, J.; Jones, L. W.; Laccetti, A. L.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Time to real-world progression (TTrwP) among patients (pts) with relapsed/refractory (R/R) testicular germ cell tumors (GCT) undergoing palliative chemotherapy (CT) in the United States (US)
    Meeting Abstract

    Feldman, D. R.; Gagnon-Sanschagrin, P.; Maitland, J.; Boileau, P.; Yokoji, K.; Guérin, A.; Guan, V.; Joseph, G.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Real-world evidence for factors associated with development of castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Ryan, C. J.; Lacuna, K. P.; Yoo, L.; Szmukier, Z.; Boldt-Houle, D. M.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A novel predictive model using changes in clinical and serum biomarkers and automated quantitative imaging for mCRPC patients treated with AR-directed therapy
    Meeting Abstract

    Morris, M. J.; Flynn, J.; Zhao, B.; Anand, A.; Sjöstrand, K.; Larson, S. M.; Scher, H. I.; Regazzi, A. M.; Borzillo, G. V.; Park, A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • DNA damage repair alterations as predictive biomarker for platinum-based chemotherapy in metastatic urothelial cancer
    Meeting Abstract

    Sternschuss, M.; Paynter, A.; Xu, W. X.; Nichols, C.; Hoppe, J.; Davis, N. B.; Jiang, D. M.; Shah, N. J.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Updated long-term follow-up from a phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy for patients with high-grade upper tract urothelial carcinoma
    Meeting Abstract

    Jayalath, V.; Teo, M. Y.; Assel, M.; Rodriguez, D.; Meyerson, A.; Bochner, B. H.; Dalbagni, G.; Donat, S. M.; Herr, H. W.; Cha, E. K.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD
    Meeting Abstract

    Le, X.; Hendriks, L.; Morabito, A.; Bonanno, L.; Okamoto, I.; Goldman, J. W.; Yu, H. A.; Brustugun, O. T.; Halvorsen, T. O.; Kim, Y. J.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save